mebendazole Side Effects
Also known as: Emverm
Analysis of 762 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
762
Death-Related
54
7.1% of reports
Hospitalizations
181
23.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 54 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| FOETAL EXPOSURE DURING PREGNANCY | 15 |
| DEATH | 11 |
| EXOMPHALOS | 7 |
| DEHYDRATION | 6 |
| FOETAL MEGACYSTIS | 6 |
| SEPSIS NEONATAL | 5 |
| DISEASE PROGRESSION | 4 |
| PNEUMONIA | 4 |
| PYREXIA | 4 |
| ABDOMINAL TENDERNESS | 3 |
| AGRANULOCYTOSIS | 3 |
| ANAEMIA | 3 |
| ASTHENIA | 3 |
| DIARRHOEA | 3 |
| METABOLIC DISORDER | 3 |
| ABDOMINAL DISTENSION | 2 |
| ADVERSE EVENT | 2 |
| ATRIAL FIBRILLATION | 2 |
| BURNING SENSATION | 2 |
| CARDIAC FAILURE | 2 |
Reactions in Hospitalization Reports
Top reactions in 181 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| NAUSEA | 23 |
| ABDOMINAL PAIN | 21 |
| VOMITING | 17 |
| PYREXIA | 15 |
| DIZZINESS | 12 |
| ASTHENIA | 11 |
| PAIN IN EXTREMITY | 10 |
| PRURITUS | 10 |
| DYSPNOEA | 9 |
| FATIGUE | 9 |
| MUSCULAR WEAKNESS | 9 |
| PNEUMONIA | 9 |
| ANXIETY | 8 |
| HEADACHE | 8 |
| HYPERTENSION | 8 |
| ABDOMINAL PAIN UPPER | 7 |
| CONVULSION | 7 |
| DECREASED APPETITE | 7 |
| OFF LABEL USE | 7 |
| ALANINE AMINOTRANSFERASE INCREASED | 6 |
Nearby — Related Medications
What the FAERS Data Reveals About mebendazole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 762 voluntary reports linked to mebendazole and its brand equivalents (Emverm), spanning 2004 through 2025. Of those, 54 (7.1%) listed death as an outcome and 181 (23.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 39% male; age distribution skews toward 0-17, with 182 reports in that bracket. The single most reported reaction is foetal exposure during pregnancy with 56 submissions, followed by nausea and vomiting.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.